FDA Grants 510(k) Clearance for Chronic Pain Relief Technology

Share this content:
Quell was designed for patients with back pain, arthritis pain, nerve pain, and leg and foot pain.
Quell was designed for patients with back pain, arthritis pain, nerve pain, and leg and foot pain.

The US Food and Drug Administration (FDA) granted 510(k) clearance to NeuroMetrix for an upgraded version of Quell, the medical technology company's chronic pain relief wearable.

“This 510(k) further advances Quell technology by allowing the device to be conveniently and safely controlled via a smartphone,” Shai Gozani, MD, PhD, president and CEO NeuroMetrix, said in a statement.

TRENDING ON CPA: More than 75% of High School Heroin Users Started With Prescription Opioids 

Through the Quell Relief smartphone app, the device, which provides nerve stimulation to patients with chronic pain, can be controlled directly by users, enabling them to adjust therapies. The app also includes several additional enhancements, including extended battery life and advanced sleep tracking.

Quell was designed for patients with back pain, arthritis pain, nerve pain, and leg and foot pain.

The latest version of Quell will be made be available in March 2016. 

You must be a registered member of Clinical Pain Advisor to post a comment.